Results 181 to 190 of about 3,292,689 (405)

Pituitary Tumor-Transforming Gene: Physiology and Implications for Tumorigenesis [PDF]

, 2007
George Vlotides, Tamar Eigler, Шломо Мелмед   +2 more
openalex   +1 more source

miR-133 inhibits pituitary tumor cell migration and invasion via down-regulating FOXC1 expression.

Genetics and Molecular Research, 2016
Dong-sheng Wang, Hongqiang Zhang, Bao-Jing Zhang, Zhongbo Yuan, Zhikuan Yu, T. Yang, Zhang Sq, Ying Liu, Jia Xx   +8 more
semanticscholar   +1 more source

Infection control in the brain and the eye

Acta Ophthalmologica, EarlyView.
Abstract The Central Nervous System (CNS), comprising the brain and the eye, is considered to have a ‘privileged’ mechanism for dealing with immunological challenge (immune privilege, IP). CNS IP has been revealed through experiments using foreign protein antigens and cell and tissue alloantigens (grafts), but evidence for a role for IP in modulating ...
John V. Forrester, Paul G. McMenamin, Samantha J. Dando   +2 more
wiley   +1 more source

A False Pituitary Tumor. [PDF]

JCEM Case Rep, 2023
Hurtado Andrade MD, Tama E, Atkinson JLD, Chang AY.   +3 more
europepmc   +1 more source

Genocopy of EVI1‐AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking

British Journal of Haematology, EarlyView.
Summary Diabetes insipidus (DI) in patients with acute myeloid leukaemia (AML) and chromosome 3q alterations (EVI1/PRDM3/MECOM overexpression) constitutes a poorly understood paraneoplasia. A 44‐year‐old patient presented with clinical and morphological features of this syndrome but, surprisingly, disclosed the rare translocation t(1;2)(p36;p21), with ...
Julian List, Etienne Sollier, Fiona Brown‐Burke, Katherine Kelly, Dietmar Pfeifer, Valeria Shlyakhto, Kristina Maas‐Bauer, Milena Pantic, Christoph Plass, Michael Lübbert   +9 more
wiley   +1 more source

Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report

BMC Endocrine Disorders
Background Growth hormone (GH) positive pituitary neuroendocrine tumors do not always cause acromegaly. Approximately one-third of GH-positive pituitary tumors are classified as non-functioning pituitary tumors in clinical practice.
Tongxin Xiao, Xinxin Mao, Ou Wang, Yong Yao, Kan Deng, Huijuan Zhu, Lian Duan   +6 more
doaj   +1 more source

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

, 2018
Daniel Bengtsson, Henrik Daa Schrøder, Katarina Berinder, Dominique Maiter, Charlotte Höybye, Óskar Ragnarsson, Ulla Feldt‐Rasmussen, Å.K. Rasmussen, Aart van der Lely, Maria Petersson, Gudmundur Johannsson, Marianne Andersen, Pia Burman   +12 more
openalex   +2 more sources

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Editorial: pituitary tumors [PDF]

Journal of Neuro-Oncology, 2014
Marvin, Bergsneider, Anthony P, Heaney, John Y K, Lee   +2 more
openaire   +2 more sources

Transsphenoidal Resection of Pituitary Tumors in the United States, 2009 to 2011: Effects of Hospital Volume on Postoperative Complications

, 2020
Daphne Li, Stephen J. Johans, Brendan Martin, Adrienne N. Cobb, Miri Kim, Anand V. Germanwala   +5 more
openalex   +2 more sources